Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness [Internet]

Khai Tran; Kathryn Coyle; Mohammed F. Jabr; Doug Coyle; Michel Boucher; Lisa Mielniczuk; John R. Swiston; Danielle Rabb; Karen Cimon; Julie Blouin; Michael Innes

Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness [Internet]

Review

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Mar.

CADTH Therapeutic Reviews.

Authors

Affiliations

¹ Canadian Agency for Drugs and Technologies in Health (CADTH, Ottawa, Ontario
² Brunel University, Uxbridge, Middlesex, United Kingdom
³ University of Ottawa, Ottawa, Ontario
⁴ Ottawa Health Research Institute, Ottawa, Ontario
⁵ University of Ottawa Heart Institute, Ottawa, Ontario
⁶ University of British Columbia, Vancouver, British Columbia

PMID: 27077175
Bookshelf ID: NBK355844

Excerpt

The objective of this therapeutic review is to conduct a systematic review to assess the comparative efficacy and safety and to determine the cost-effectiveness of drug therapies for the treatment of pulmonary arterial hypertension (PAH) in adults.

Sections

ABBREVIATIONS AND GLOSSARY
EXECUTIVE SUMMARY
1. CONTEXT AND POLICY ISSUES
2. POLICY QUESTIONS
3. RESEARCH QUESTIONS
4. METHODS
5. RESULTS
6. DISCUSSION
7. CONCLUSIONS AND IMPLICATIONS FOR DECISION-OR POLICY-MAKING
REFERENCES
APPENDIX 1. PATIENT INPUT INFORMATION
APPENDIX 2. VALIDITY OF OUTCOMES
APPENDIX 3. LITERATURE SEARCH STRATEGY
APPENDIX 4. SELECTION OF INCLUDED STUDIES
APPENDIX 5. INCLUDED STUDY LIST
APPENDIX 6. EXCLUDED STUDY LIST
APPENDIX 7. CHARACTERISTICS OF INCLUDED STUDIES
APPENDIX 8. CRITICAL APPRAISAL OF INCLUDED STUDIES
APPENDIX 9. DETAILED DATA OF MONOTHERAPY AND ADD-ON THERAPY TRIALS
APPENDIX 10. PAIRWISE META-ANALYSES
APPENDIX 11. COMPARISONS OF PAIRWISE META-ANALYSES AND NETWORK META-ANALYSES
APPENDIX 12. COMPLETE RESULTS OF NETWORK META-ANALYSIS
APPENDIX 13. QUALITY OF LIFE
APPENDIX 14. COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION — STUDIES NOT INCLUDED IN THERAPEUTIC REVIEW
APPENDIX 15. REVIEW OF PREVIOUS PHARMACOECONOMIC ANALYSES
APPENDIX 16. SCHEMATIC OF MARKOV MODEL
APPENDIX 17. CLINICAL PARAMETERS FOR THE ECONOMIC MODEL
APPENDIX 18. RESOURCE USE ESTIMATES FOR THE ECONOMIC MODEL
APPENDIX 19. BREAKDOWN OF COSTS BY COST CATEGORY

Publication types

Review